PIL- Telmisartan/Hydrochlorothiazide 40mg/12.5mg, 80mg/12.5mg, 80mg/25mg Tablets: Change history
View Patient Information Leaflet (PIL- Telmisartan/Hydrochlorothiazide 40mg/12.5mg, 80mg/12.5mg, 80mg/25mg Tablets)
Last updated on this site: 27 Apr 2026
Description of update: Type IB (C.2.a) variation application to update sections 4.2, 4.3, 4.4, 4.5, 4.6, 4.7, 4.8, 4.9, 5.1, 5.2, 5.3 of the SPC and sections 1, 2, 3 and 4 of the leaflet in-line with the product information of reference product (MicardisPlus 40 mg/12.5 mg, 80 mg/12.5 mg and 80 mg/25 mg tablets; MAH: Boehringer Ingelheim International GmbH, Germany; procedure number: EMEA/H/C/000413).
Date of approval: 22/04/2026
PIL sections updated: 1, 2, 3, 4 and 6
Last updated on this site: 27 Apr 2026
Description of update: Type IB (C.2.a) variation application to update sections 4.2, 4.3, 4.4, 4.5, 4.6, 4.7, 4.8, 4.9, 5.1, 5.2, 5.3 of the SPC and sections 1, 2, 3 and 4 of the leaflet in-line with the product information of reference product (MicardisPlus 40 mg/12.5 mg, 80 mg/12.5 mg and 80 mg/25 mg tablets; MAH: Boehringer Ingelheim International GmbH, Germany; procedure number: EMEA/H/C/000413).
Date of approval: 22/04/2026
PIL sections updated: 1, 2, 3, 4 and 6
-
Changes: (Updated: 27 Apr 2026)
Description of update: Type IB (C.2.a) variation application to update sections 4.2, 4.3, 4.4, 4.5, 4.6, 4.7, 4.8, 4.9, 5.1, 5.2, 5.3 of the SPC and sections 1, 2, 3 and 4 of the leaflet in-line with the product information of reference product (MicardisPlus 40 mg/12.5 mg, 80 mg/12.5 mg and 80 mg/25 mg tablets; MAH: Boehringer Ingelheim International GmbH, Germany; procedure number: EMEA/H/C/000413).
Date of approval: 22/04/2026
PIL sections updated: 1, 2, 3, 4 and 6
-
Changes: (Updated: 13 May 2025)
Update to SmPC sections 4.4, 4.8 and PIL sections 2 and 4 in line with PRAC recommendations (EPITT No 20104) for intestinal angioedema.
-
Changes: (Updated: 22 Sep 2022)
initial upload